Admak Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 27-06-2024
- Paid Up Capital ₹ 0.10 M
as on 27-06-2024
- Company Age 9 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -50.03%
(FY 2022)
- Profit 68.58%
(FY 2022)
- Ebitda 86.11%
(FY 2022)
- Net Worth -1.92%
(FY 2022)
- Total Assets -1.45%
(FY 2022)
About Admak Pharmaceuticals
The Corporate was formerly known as Ady Solutions Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Yadav, Sunita Yadav, and Amit Yadav serve as directors at the Company.
- CIN/LLPIN
U24100MH2015PTC266651
- Company No.
266651
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jul 2015
- Date of AGM
13 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Admak Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Yadav  | Director | 01-Apr-2017 | Current |
| Sunita Yadav | Director | 11-Mar-2021 | Current |
| Amit Yadav | Director | 15-Jul-2015 | Current |
Financial Performance and Corporate Structure Insights of Admak Pharmaceuticals.
Admak Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 50.03% decrease. The company also saw a substantial improvement in profitability, with a 68.58% increase in profit. The company's net worth dipped by a decrease of 1.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Admak Pharmaceuticals?
In 2021, Admak Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Seraph Life Sciences Private Limited
Active 11 years 9 monthsSunita Yadav and Amit Yadav are mutual person
Adsra Logistics Private Limited
Active 6 years 10 monthsSunita Yadav and Amit Yadav are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Admak Pharmaceuticals?
Unlock and access historical data on people associated with Admak Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Admak Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Admak Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
